Showing results (2121-2130 of 2,239) with videos related to
Sort By:
Pageof 224
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLCMei-Mei Zheng, Yang-Si Li, Ben-Yuan Jiang, et al.Thoracic Cancer|September 7, 2021
High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancerHui-Bo Feng, Yu Chen, Zhi Xie, et al.Future Oncology (London, England)|November 1, 2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancerYi-Long Wu, Masahiro Tsuboi, Thomas John, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2019
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II StudyWen-Zhao Zhong, Ke-Neng Chen, Chun Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 10, 2024
Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal StudyQing Zhou, Xiangjiao Meng, Longhua Sun, et al.Biorxiv : the Preprint Server for Biology|February 27, 2026
Reprogramming CAR T-Cells with designed bioPROTACsVivek S Peche, Sebastian Kenny, Tae Gun Kang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 1, 2017
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung AdenocarcinomaZhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2025
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN StudyYi-Long Wu, Hye Ryun Kim, Ross A Soo, et al.Biomarker Research|July 23, 2025
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective studyChang Lu, Chong-Rui Xu, Yi-Chen Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2022
Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA TrialMargarita Majem, Jonathan W Goldman, Thomas John, et al.Pageof 224